Premium
Antiangiogenic metronomic chemotherapy and hyperthermia in the palliation of advanced cancer
Author(s) -
FRANCHI F.,
GRASSI P.,
FERRO D.,
PIGLIUCCI G.,
DE CHICCHIS M.,
CASTIGLIANI G.,
PASTORE C.,
SEMINARA P.
Publication year - 2007
Publication title -
european journal of cancer care
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.849
H-Index - 67
eISSN - 1365-2354
pISSN - 0961-5423
DOI - 10.1111/j.1365-2354.2006.00737.x
Subject(s) - medicine , hyperthermia , coagulative necrosis , chemotherapy , cancer , oncology , palliative therapy
Among a large series of cancer patients treated with a combination of chemotherapy and sessions of hyperthermia, particular attention was given to a specific group of patients with advanced cancer who refused standard, aggressive, treatment. In these cases, hyperthermia was associated to low‐dose (metronomic) chemotherapy. No toxicity was reported in any of our patients, while a marginal benefit in terms of tumour progression was observed. During therapy, we could detect a coagulative perturbation that deserves careful discussion. In our opinion, this experience should be matter of debate to conclude if current response criteria (WHO/UICC and RECIST) in treating cancer patients are really suitable tools to evaluate new, and non‐aggressive anticancer strategies.